{"paper_id":"381b9b8c-8ec3-4b48-9661-3e51a004dc98","body_text":"Abstract\nEndometriosis is a non-malignant, estrogen-dependent chronic inflammatory disorder that affects 10–15% of women during their reproductive years. Emerging evidence highlights the undeniable role of oxidative stress in the etiopathogenesis of endometriosis. Selenium, a potent antioxidant, is vital for intracellular redox reactions. Recent research has highlighted the potential of antioxidants as therapeutic agents to mitigate oxidative stress and alleviate endometriosis symptoms. Selenium plays a key role in regulating the enzyme glutathione peroxidase (GPx). This study aimed to evaluate the therapeutic efficacy of a yeast-based organic selenium in disease progression and alleviating painful symptoms. This triple-blind randomized controlled clinical trial was executed within 66 women diagnosed with endometriosis in Tabriz, Iran. Participants were required to possess diagnostically verified endometriosis with endometrioma and a dysmenorrhea score of ≥ 16 on the Menstrual Distress Questionnaire (Moos). Using block randomization with block sizes of 4 or 6, participants were assigned (1:1 ratio) to receive either one 200-mcg capsule of organic selenium or an identical placebo along with routine treatment (2 mg of verojest (dienogest) daily for 3 months). Data were collected using socio-demographic and menstrual-obstetric questionnaires, the Moos, and the visual analogue scale (VAS) for pain. After 3 months, participants completed follow-up questionnaires and underwent ultrasonography. Statistical analyses included descriptive and inferential tests (chi-square, independent t-test, ANCOVA, and repeated-measures ANOVA). A p-value of < 0.05 was considered statistically significant. Three months after the intervention, a statistically significant reduction in endometrioma size was observed in the selenium group (from 4.82 to 3.78 cm) compared to placebo (from 4.07 to 5.31 cm) (adjusted mean difference [aMD]: −1.95 cm; 95% CI −2.6 to −1.3; Cohen’s d = –0.86, large effect). Additionally, the selenium group experienced significantly greater reductions in dysmenorrhea scores (aMD −10.94; 95% CI −15.16 to −6.71; Cohen’s d = –1.14, large effect), dyspareunia (aMD −3.21; 95% CI −4.34 to −2.07), dysuria (aMD −1.41; 95% CI −2.12 to −0.69), dyschezia (aMD −2.11; 95% CI −3.22 to −0.99), and non-cyclic pain (aMD −2.73; 95% CI −3.77 to −1.68) over time (at 1, 2, and 3 months post-intervention), compared to placebo. No serious or health-threatening adverse events were reported in either group. Our findings support the hypothesis that organic selenium supplementation may present a promising adjuvant therapy to reduce the size of endometriomas and alleviate various painful symptoms associated with endometriosis, including dysmenorrhea, dyspareunia, dysuria, non-cyclic pain, and dyschezia. ClinicalTrial.gov Identifier: IRCT20110606006709N26.\nSimilar content being viewed by others\nData Availability\nData will be made available by the corresponding author on request.\nAbbreviations\n- MMQD :\n-\nMoos Menstrual Distress Questionnaire\n- VAS :\n-\nVisual analogue scale\n- ROS :\n-\nReactive oxygen species\n- GPX :\n-\nGlutathione peroxidase\n- TNF-α :\n-\nTumor necrosis factor-alpha\n- IL-1β :\n-\nInterleukin-1 beta\n- ICP-MS :\n-\nInductively coupled plasma mass spectrometry\n- RAS :\n-\nRandom Allocation Software\n- EFSA :\n-\nEuropean Food Safety Authority\nReferences\nYavari M, Vallian BS (2022) The role of genetics in endometriosis. J Laboratory & Diagnosis 14(57):42–47\nAgarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, et al (2019) Clinical diagnosis of endometriosis: a call to action. Am j obstet gynecol 220(4):354.e1-.e12\nThomas EJ, Rock J (2012) Modern approaches to endometriosis. Springer, Netherlands\nTavoli Z, Asgari Z, Afshari F, Tabatabaei F, Montazeri A (2020) Recurrence rate of endometrioma after laparoscopic bilateral cystectomy and unilateral cystectomy and drainage in opposite side. J The Iranian Journal of Obstetrics, Gynecology and Infertility 23(3):19–25\nRasekhi M, ZaeimYekeh MA (2020) Simultaneous appearance of dermoid cyst and endometrioma in one ovary. Sarem Journal of Reproductive Medicine 5(2):82–85\nWarzecha D, Szymusik I, Wielgos M, Pietrzak B (2020) The impact of endometriosis on the quality of life and the incidence of depression-a cohort study. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph17103641\nBorghese B, Santulli P, Streuli I, Lafay-Pillet MC, de Ziegler D, Chapron C (2014) Recurrence of pain after surgery for deeply infiltrating endometriosis: how does it happen? How to manage? J Gynecol Obstet Biol Reprod 43(1):12–18\nNisenblat V, Bossuyt PM, Farquhar C, Johnson N, Hull ML (2016) Imaging modalities for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev 2(2):Cd009591\nSantanam N, Kavtaradze N, Murphy A, Dominguez C, Parthasarathy S (2013) Antioxidant supplementation reduces endometriosis-related pelvic pain in humans. Transl Res 161(3):189–195\nTriolo O, Laganà AS, Sturlese E (2013) Chronic pelvic pain in endometriosis: an overview. J Clin Med Res 5(3):153–163\nZubrzycka A, Zubrzycki M, Perdas E, Zubrzycka M (2020) Genetic, epigenetic, and steroidogenic modulation mechanisms in endometriosis. J Clin Med. https://doi.org/10.3390/jcm9051309\nScutiero G, Iannone P, Bernardi G, Bonaccorsi G, Spadaro S, Volta CA, et al (2017) Oxidative stress and endometriosis: a systematic review of the literature. Oxidative med cell longev 20. 7265238;17\nEk M, Roth B, Ekström P, Valentin L, Bengtsson M, Ohlsson B (2015) Gastrointestinal symptoms among endometriosis patients–a case-cohort study. BMC Womens Health 15:59\nKe X, Qian H, Kang L, Wang J, Xie Y, Cheng Z (2015) Clinical analyses of endometriosis after conservative surgery. Int J Clin Exp Med 8(11):21703–21706\nMuzii L, Di Tucci C, Achilli C, Di Donato V, Musella A, Palaia I (2016) Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol 214(2):203–211\nMuñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, Alvarez-Conejo C, Tejerizo-García Á, Lopez-Gonzalez G et al (2015) Endometriosis: alternative methods of medical treatment. Int J Women’s Health 7:595–603\nHaug A, Graham RD, Christophersen OA, Lyons GH (2007) How to use the world’s scarce selenium resources efficiently to increase the selenium concentration in food. Microb Ecol Health Dis 19(4):209–228\nLanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC et al (2005) Low-level environmental lead exposure and children’s intellectual function: an international pooled analysis. Environ Health Perspect 113(7):894–899\nZoidis E, Seremelis I, Kontopoulos N, Danezis GP (2018) Selenium-dependent antioxidant enzymes: actions and properties of selenoproteins. Antioxidants (Basel, Switzerland). https://doi.org/10.3390/antiox7050066\nLu J, Holmgren A (2009) Selenoproteins. J Biol Chem 284(2):723–727\nTóth RJ, Csapó J (2018) The role of selenium in nutrition—a review. Acta Universitatis Sapientiae, Alimentaria 11:128–144\nSchrauzer GN (2003) The nutritional significance, metabolism and toxicology of selenomethionine. Adv Food Nutr Res 47:73–112\nYalçın Bahat P, Ayhan I, Üreyen Özdemir E, İnceboz Ü, Oral E (2022) Dietary supplements for treatment of endometriosis: a review. Acta Biomed Atenei Parmensis 93(1):e2022159\nPiecuch M, Garbicz J, Waliczek M, Malinowska-Borowska J, Rozentryt P (2022) I am the 1 in 10-what should i eat? A research review of nutrition in endometriosis. Nutrients. https://doi.org/10.3390/nu14245283\nGuo JJ, Li RX, Shang WL, Zheng YF, Zhu GY, Shu ZC, Liu GC, Ou HB, Li J, Guo XG, Lin LH (2025) Association between dietary selenium intake and endometriosis risk: a cross-sectional analysis. Front Endocrinol 16:1486790\nBaradwan S, Gari A, Sabban H, Alshahrani MS, Khadawardi K, Bukhari IA et al (2024) The effect of antioxidant supplementation on dysmenorrhea and endometriosis-associated painful symptoms: a systematic review and meta-analysis of randomized clinical trials. Obstet Gynecol Sci 67(2):186–198\nEFSA Panel on Nutrition, Foods Novel, Allergens Food, (NDA), Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst KI, Knutsen HK, Maciuk A, Mangelsdorf I, McArdle HJ, Peláez C (2023Jan) Scientific opinion on the tolerable upper intake level for selenium. EFSA J 21(1):e07704\nRahimi P, Farshbaf-Khalili A, Shahnazi M, Ostarahimi A, Mohammadi M (2024) Comparing the effects of selenium-enriched yeast and sodium selenite supplementation on postpartum depression and sexual satisfaction: a triple-blind controlled clinical trial. J Caring Sci 13(3):197–206\nQorbanalipour K, Ghaderi F, Asghari Jafarabadi M, Mohammadalizade Charandabi S (2016) Validity and reliability of the Persian version of modified Moos menstrual distress questionnaire. J The Iranian J Obstet, Gynecol Infertility 19(29):11–8\nRana Modabber E, Hamdi K, Fardiazar Z (2019) Comparison of suppressive hormonal therapy (low dose oral contraceptive) and aspiration in regression of ovarian endometrioma\nYucel N, Baskent E, Karamustafaoglu Balci B, Goynumer G (2018) The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis. Aust N Z J Obstet Gynaecol 58(5):560–3\nHosseinzadeh FM, Hosseinzadeh-Attar MJ, Yekaninejad MS, Rashidi B (2016) Effects of selenium supplementation on glucose homeostasis and free androgen index in women with polycystic ovary syndrome: a randomized, double blinded, placebo controlled clinical trial. J Trace Elem Med Biol 34:56–61\nNazıroğlu M, Öz A, Yıldızhan K (2023) Selenium and neurological diseases: focus on peripheral pain and TRP.\nMehrpooya M, Majmasanaye M, Faramarzi F, Eshraghi A, Faress F (2023) Investigation of the effect of oral selenium on the reduction of clinical symptoms and joint pain in patients with rheumatoid arthritis in the Iranian population. J Clin Pharmacol 63(11):1197–204\nRayman MP (2012) Selenium and human health. Lancet 379(9822):1256–68\nKiełczykowska M, Kocot J, Paździor M, Musik I (2018) Selenium-a fascinating antioxidant of protective properties. Adv Clin Exp Med 27(2):245–55\nHoffmann PR, Berry MJ (2008) The influence of selenium on immune responses. Mol Nutr Food Res 52(11):1273–80\nHernández Guerrero CA, Bujalil Montenegro L, de la Jara Díaz J, Mier Cabrera J, Bouchán Valencia P (2006) [Endometriosis and deficient intake of antioxidants molecules related to peripheral and peritoneal oxidative stress]. Ginecologia y obstetricia de Mexico 74(1):20–8\nZheng S-H, Chen X-X, Chen Y, Wu Z-C, Chen X-Q, Li X-L (2023) Antioxidant vitamins supplementation reduce endometriosis related pelvic pain in humans: a systematic review and meta-analysis. Reprod Biol Endocrinol 21(1):79\nAcknowledgements\nSpecial thanks and appreciation are extended to the Clinical Research Development Unit et al. – Zahra Hospital, and Therapeutic Center Sheikh Al-Rais and Tabriz University of Medical Sciences for their research consultation and support.\nFunding\nThis research was funded by the Vice-Chancellor for Research of Tabriz University of Medical Sciences, Iran. The funding center had no role in the study design, data analysis, or writing this paper.\nAuthor information\nAuthors and Affiliations\nContributions\nF.T, M.Sh., A.F-Kh. and Kh.H. contributed to the design of the study. FT and MPN contributed to the collection of data. FT., M.Sh. and A.F-Kh. contributed to the implementation and analysis plan. F.T., M.Sh, A.F-Kh., and Kh.H have written the first draft of this manuscript and all authors have critically read the text and contributed with inputs and revisions, and all authors read and approved the final manuscript. All authors reviewed the manuscript.\nCorresponding authors\nEthics declarations\nEthics Approval\nThis study was approved by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1402.570) on December 18, 2023. The trial’s protocol was also registered at the Iranian Registry for Clinical Trials (code: IRCT20110606006709N26) on December 30, 2023. Written informed consent was obtained from the participants or a parent and/or legal guardian (for minors) for study participation before starting data collection.\nConsent for Publication\nNot applicable.\nCompeting interests\nThe authors declare no competing interests.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nTeihoomaneshfard, F., Hajizadeh, K., Nasirkandy, M.P. et al. Efficacy of Organic Selenium Supplementation on Endometrioma Regression and Pain in Women With Endometriosis: A Triple-Blind Randomized Controlled Clinical Trial. Biol Trace Elem Res 204, 2542–2551 (2026). https://doi.org/10.1007/s12011-025-04837-1\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s12011-025-04837-1","source_license":"public-domain-us","license_restricted":false}